Glenmark says FabiFlu shows promise in Phase 3 coronavirus trial
Glenmark Pharmaceuticals today said its generic version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection. About 70% of patients…